Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Lazenby

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
British Medical Journal|August 27, 2010
THE TREATMENT OF IRRITANT GAS POISONINGJ M Lazenby
British Dental Journal|January 10, 2009
OTC MedicationsM Lazenby, J Anderud, M Millwaters
Biochemical Pharmacology|September 1, 1987
Effect of two inducers of cellular differentiation on the glutathione status of human HL-60 promyelocytic leukaemia and A549 lung carcinoma cellsC M Lazenby, A Gescher, I L Dale
Veterinary Pathology|January 1, 1993
Crescentic cataracts in Alderley Park ratsC M Lazenby, F R Westwood, P Greaves
Leukemia|January 8, 2011
The cyclin-dependent kinase inhibitor SNS-032 has single agent activity in AML cells and is highly synergistic with cytarabineE Walsby, M Lazenby, C Pepper, et al.
Cancer Research|June 1, 1990
Elevation of leukemic cell intracellular calcium by the ether lipid SRI 62-834C M Lazenby, M G Thompson, J A Hickman
Leukemia Research|April 18, 2015
The HSP90 inhibitor ganetespib: A potential effective agent for Acute Myeloid Leukemia in combination with cytarabineM Lazenby, R Hills, A K Burnett, et al.
Biochemical Pharmacology|October 1, 1988
Glutathione depletion in the guinea pig and its effect on the acute cochlear toxicity of ethacrynic acidC M Lazenby, S J Lee, E S Harpur, et al.
International Nursing Review|June 25, 2020
Clinical nursing and midwifery education in the pandemic ageM Lazenby, S Chambers, D Chyun, et al.
Leukemia|February 28, 2014
The prognostic relevance of flt3 and npm1 mutations on older patients treated intensively or non-intensively: a study of 1312 patients in the UK NCRI AML16 trialM Lazenby, A F Gilkes, C Marrin, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
British Medical Journal|August 27, 2010
THE TREATMENT OF IRRITANT GAS POISONINGJ M Lazenby
British Dental Journal|January 10, 2009
OTC MedicationsM Lazenby, J Anderud, M Millwaters
Biochemical Pharmacology|September 1, 1987
Effect of two inducers of cellular differentiation on the glutathione status of human HL-60 promyelocytic leukaemia and A549 lung carcinoma cellsC M Lazenby, A Gescher, I L Dale
Veterinary Pathology|January 1, 1993
Crescentic cataracts in Alderley Park ratsC M Lazenby, F R Westwood, P Greaves
Leukemia|January 8, 2011
The cyclin-dependent kinase inhibitor SNS-032 has single agent activity in AML cells and is highly synergistic with cytarabineE Walsby, M Lazenby, C Pepper, et al.
Cancer Research|June 1, 1990
Elevation of leukemic cell intracellular calcium by the ether lipid SRI 62-834C M Lazenby, M G Thompson, J A Hickman
Leukemia Research|April 18, 2015
The HSP90 inhibitor ganetespib: A potential effective agent for Acute Myeloid Leukemia in combination with cytarabineM Lazenby, R Hills, A K Burnett, et al.
Biochemical Pharmacology|October 1, 1988
Glutathione depletion in the guinea pig and its effect on the acute cochlear toxicity of ethacrynic acidC M Lazenby, S J Lee, E S Harpur, et al.
International Nursing Review|June 25, 2020
Clinical nursing and midwifery education in the pandemic ageM Lazenby, S Chambers, D Chyun, et al.
Leukemia|February 28, 2014
The prognostic relevance of flt3 and npm1 mutations on older patients treated intensively or non-intensively: a study of 1312 patients in the UK NCRI AML16 trialM Lazenby, A F Gilkes, C Marrin, et al.
Pageof 2